Initially 30 mg daily (½ tab), may be increased to 60, 90 or 120 mg daily, in successive steps. Interval between each dose increment should be at least 1 mth except in patients whose blood glucose has not reduced after 2 wk of treatment. Dose may be increased at the end of the 2nd wk of treatment in such cases. Max daily dose: 120 mg. Switching from gliclazide tab 80 mg to gliclazide MR tab 60 mg 1 tab of gliclazide 80 mg tab is comparable to 30 mg MR formulation (ie, ½ tab of GliXa 60 mg). Consequently, the switch can be performed w/ careful blood monitoring. Switching from another oral antidiabetic agent to gliclazide MR tab 60 mg Initially 30 mg/day, followed by a stepwise increase in dose, depending on the metabolic response. Patient at risk of hypoglycemia Min starting dose of 30 mg daily.
View GliXa overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food: Take at breakfast. Swallow whole, do not crush or chew.
Contraindications
Hypersensitivity to gliclazide, other sulfonylureas or sulfonamides. Type 1 diabetes; diabetic pre-coma & coma, diabetic ketoacidosis. Concomitant use w/ miconazole. Severe renal or hepatic insufficiency. Lactation.
Risk of hypoglycemia especially during low-calorie diets following prolonged or strenuous exercise, alcohol intake or if in combination w/ hypoglycemic agents. Malnutrition, irregular mealtimes, skipping meals, periods of fasting or dietary changes; imbalance between physical exercise & carbohydrate intake. Thyroid disorders, hypopituitarism & adrenal insufficiency. St. John's wort prep, fever, trauma, infection or surgery may affect blood glucose control. Dysglycemia in diabetic patients receiving concomitant use w/ fluoroquinolones, especially in elderly. Monitor blood glucose regularly. G6PD-deficiency. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Renal & hepatic insufficiency. May impair ability to drive or operate machinery. Pregnancy. Childn & adolescents.
Sign Out
